Relebactam

Synonym(s): MK-7655

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Details of activity:	DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D beta-lactamases. No intrinsic antibacterial activity
Combined with other compounds:	Yes
Description:	Synthetic compound. 2019 approved in fixed combination with imipenem/cilastatin (Recarbrio)
Institute where first reported:	Merck Sharp & Dohme
Year first mentioned:	2009
Highest developmental phase:	Approved by FDA in 2019
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1C[C@@H](C(=O)NC2CCNCC2)N3C[C@@H]1N(C3=O)OS(=O)(=O)O
Isomeric SMILES:	C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
InChI:	InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1
InChI Key:	SMOBCLHAZXOKDQ-ZJUUUORDSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/44129647

External links:
Guide to Pharmacology:	relebactam
Main Source:	https://www.sciencedirect.com/science/article/abs/pii/S136952741100110X?via%3Dihub